Jul 30, 2023, 06:33
Merck announces positive results for KEYNOTE-756
In a post by Paolo Tarantino on Twitter, it says, “Merck announces positive results for KEYNOTE-756: the addition of pembrolizumab to neoadjuvant chemo significantly improved pCR rate among patients with high-risk HR+/HER2- breast cancer. Follow up ongoing for EFS (co-primary endpoint).”
For the article: Click here
Source:Paolo Tarantino / Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12